Basgenbio
Vaszenio is a bio-vitator based on artificial intelligence that offers more than health value.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | KRW10.0b | Series B | |
| Total Funding | 000k | ||
Related Content
Operating from Seoul, South Korea, Basgenbio is a biotechnology firm established in 2018 that specializes in preventative and precision medicine by leveraging big data and artificial intelligence. The company was formerly known as Tubico.
The company's core asset is its access to the K-Biobank, a comprehensive clinico-genomic cohort database of 156,000 Korean subjects which includes blood samples, clinical and lifestyle information, with an 18-year maximum follow-up period. This dataset is the foundation for Basgenbio's AI-driven platforms. The firm serves medical institutions and pharmaceutical companies, providing data-driven insights to aid in drug development and pipeline management. Its business model revolves around partnerships and joint R&D agreements with pharmaceutical firms, such as the one established with Celltrion for genomics-based biomarker discovery.
Basgenbio has developed several key products. The Clinico-Omics Cohort Database (COCD) platform integrates the K-Biobank with other global biobanks. Built upon this platform is DEEPCT™ (DEEP learning-based Clinical Trial), a simulation tool that predicts drug efficacy and side effects, identifies optimal drug combinations, and explores new indications for existing drugs. Another product, TLBM™ (Time-Labeled BioMarker), provides time-series analysis of disease risk, which was licensed out to a molecular diagnostic company for gastric cancer. The company is also actively working to establish biobanks for aging-related and rare diseases in collaboration with industry partners.
Since its founding, Basgenbio has secured a total of $7.61M in funding, including a Series A round in 2021 led by DS Asset Management. The company has achieved significant recognition, including being named a 'Baby Unicorn 200' by the Korean Ministry of SMEs and Startups and winning first place at the '3rd Health X Challenge Seoul' hosted by Novartis and Seoul City. The management team includes CEO Il-Tae Jang, a medical doctor, and CEO Ho Kim, who specializes in genetic epidemiology R&D.
Keywords: biotechnology, precision medicine, big data analytics, artificial intelligence, drug development, genomic cohort, biomarker discovery, clinical trial simulation, bioinformatics, healthcare data